Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 16/20 | 1.00 |
| ▸ | PRSS1 | P07477 | 11/20 | 1.00 |
| ▸ | F10 | P00742 | 8/20 | 1.00 |
| ▸ | PLG | P00747 | 2/20 | 0.57 |
| ▸ | PLAU | P00749 | 2/20 | 0.57 |
| ▸ | F12 | P00748 | 1/20 | 0.57 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.57 |
| ▸ | PROC | P04070 | 1/20 | 0.57 |
| ▸ | HPN | P05981 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5103964 | 0.99 | F2 (0.98) | F2PRSS1F10PLGPLAU | |
| SCHEMBL14289390 | 0.92 | F2 (1.00) | F2PRSS1F10PLGPROC | |
| Hydrochloric Acid SCHEMBL5110448 | 0.91 | F2 (0.98) | F2PRSS1F10PLGPROC | |
| SCHEMBL5109231 | 0.91 | F2 (0.83) | F2PRSS1F10PLGPLAU | |
| SCHEMBL5109227 | 0.90 | F2 (1.00) | F2PRSS1F10PLAU | |
| SCHEMBL5109223 | 0.90 | F2 (1.00) | F2PRSS1F10PLAU | |
| SCHEMBL8242185 | 0.90 | F2 (1.00) | F2PRSS1F10PLGPLAU | |
| SCHEMBL13990458 | 0.90 | F2 (1.00) | F2PRSS1F10PLGPLAU | |
| Hydrochloric Acid SCHEMBL5109207 | 0.89 | F2 (0.98) | F2PRSS1F10PLGPLAU | |
| SCHEMBL5103963 | 0.84 | F2 (0.73) | F2PRSS1F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080004256-A1 | Amidinophenylalanine Derivatives as Thrombin Inhibitors | LEK PHARMACEUTICALS D.D. (SI) | 2008-01-03 | — | — | US | disclosed |
| US-20080004256-A1 | Amidinophenylalanine Derivatives as Thrombin Inhibitors | LEK PHARMACEUTICALS D.D. (SI) | 2008-01-03 | — | — | US | disclosed |
| US-7285547-B2 | Amidinophenylalanine derivatives as thrombin inhibitors | LEK PHARMACEUTICALS D.D. (SI) | 2007-10-23 | — | — | US | disclosed |
| US-7285547-B2 | Amidinophenylalanine derivatives as thrombin inhibitors | LEK PHARMACEUTICALS D.D. (SI) | 2007-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004256-A1 | Amidinophenylalanine Derivatives as Thrombin Inhibitors | TFPI, SERPINC1, F2 | F2 3/4885PRSS1 34/4885F10 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.